At its debut 2 years ago, a vaccine that pre-vents cervical cancer was heralded as a public health breakthrough that could poten-tially save millions of women’s lives. Yet although the vaccine is now given routinely to young girls in the United States and Europe, it hasn’t been deployed in poorer countries, where it could make a bigger difference.
February 10, 2015
Thanks to Pap tests, fatal cervical cancers are almost unknown today in rich countries. But the disease kills an estimated 275,000 women a year in poor countries where Pap tests are impractical and the vaccine is far too expensive for the average woman to afford, so the price cut could lead to a significant advance in women’s health.